In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on GH Research (GHRS – Research Report), with a price target of $45.00. The company’s shares opened today at $12.63.
According to TipRanks, Trucchio is an analyst with an average return of -17.9% and a 29.90% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Oncolytics Biotech, and Alnylam Pharma.
Currently, the analyst consensus on GH Research is a Strong Buy with an average price target of $39.67.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $17.41 and a one-year low of $5.70. Currently, GH Research has an average volume of 62.79K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Read More on GHRS:
- ‘It’s Really a Brain Chemistry Issue’: Elon Musk Embraces Ketamine for Depression — Here Are 2 Psychedelic Stocks That Analysts Like, Including One With Over 400% Upside
- GHRS Earnings this Week: How Will it Perform?
- GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
